Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

NCT03484221 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Rectal Neoplasms
Drug Therapy
Radiation

Interventions

DRUG: FOLFOXIRI
RADIATION: Short-Course Radiation Therapy(5Gy*5)
DRUG: XELOX

Sponsor

China Medical University, China